Seaport Therapeutics (SPTX) Conference presentation summary

Market opportunity and unmet need

• Over 1 billion people globally suffer from mental illness, with depression and anxiety highly comorbid and associated with significant disability and mortality.

• Current neuropsychiatric medications have limitations, including modest efficacy, slow onset, and unfavorable side effects, leaving many patients inadequately treated.

• The neuropsychiatry drug development landscape is challenging, with a >90% clinical trial failure rate due to poor drug properties and complex clinical studies.

Platform and innovation

• The proprietary Glyph™ platform enables oral delivery of drugs previously limited by high first-pass metabolism, improving bioavailability and reducing hepatotoxicity.

• Glyph™ leverages lymphatic absorption to bypass the liver, generating new intellectual property and reducing pharmacokinetic variability.

• The platform has been successfully applied to over 24 small molecules, creating a robust pipeline and strong composition of matter IP.

Pipeline and clinical progress

• Lead program GlyphAllo™ (SPT-300) targets major depressive disorder (MDD), showing >9x oral bioavailability versus unmodified allopregnanolone and favorable tolerability.

• Phase 2a results demonstrated significant reduction in stress response and initial proof-of-concept for MDD, with a Phase 2b BUOY-1 trial underway and topline data expected 1H 2027.

• GlyphAgo™ (SPT-320) for generalized anxiety disorder (GAD) achieved a 6.8-fold increase in bioavailability and 10-fold reduction in PK variability versus agomelatine, with no liver-related adverse events.

• Glyph2BLSD™ (SPT-348) is designed to harness neuroplastic effects of psychedelics without hallucinations, enabling outpatient dosing.